MedTrace Logo

Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease

NCT00102115 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2010-03-12

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of Talaporfin Sodium (LS11) Photodynamic Therapy in patients with late stage Age-Related Macular Disease (AMD).

Conditions

  • Macular Degeneration
  • Choroidal Neovascularization

Interventions

DRUG

Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)

Sponsors & Collaborators

  • Light Sciences LLC

    lead INDUSTRY

Principal Investigators

  • Gary Krasner, PhD · Light Sciences LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2006-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00102115 on ClinicalTrials.gov